Experimental combo therapy shows promise for Tough-to-Treat lymphomas
NCT ID NCT04074746
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 35 times
Summary
This early-phase trial tested a new approach for people with CD30-positive Hodgkin or non-Hodgkin lymphomas that returned or didn't respond to standard treatments. Participants received a combination of AFM13 (an antibody that helps immune cells target cancer) and natural killer (NK) cells from donated umbilical cord blood. The goal was to see if this combo is safe and can shrink tumors. The study enrolled 45 patients and measured side effects, survival, and response rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CLASSIC HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AFM13 (an antibody that helps immune cells attack cancer) combined with natural killer (NK) cells from donated umbilical cord blood
What this could lead to
If it works, this could offer a new treatment option for people with certain lymphomas that have come back or stopped responding to other therapies.
What could go wrong
This is an early-phase trial with only 45 participants, so results may not apply to everyone. Side effects are possible, and the treatment may not work for all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.